Agoracom Blog Home

Posts Tagged ‘Hemp’

CLIENT FEATURE: AppliedBiosciences: Diversified in Multiple Areas of Hemp and CBD Industry $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM at 9:03 AM on Thursday, October 18th, 2018

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

Why AppliedBiosciences?

    • Diversified company focused on multiple areas of the Hemp and CBD Industry
    • Focused on opportunities in the recreational, health and wellness, nutraceutical and media industries
    • Several Strategic Partnerships in place

Multiple Product Lines:

Hub On AGORACOM

FULL DISCLOSURE: AppliedBiosciences is an advertising client of AGORA Internet Relations Corp.

Canada to Open More Than 100 Pot Shops as It Becomes the Second Country to Legalize Marijuana $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 2:26 PM on Thursday, October 11th, 2018

  • On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace. Uruguay launched legal sales last year, after several years of planning.
  • It’s a profound social shift promised by Canadian Prime Minister Justin Trudeau and fueled by a desire to bring the black market into a regulated, taxed system after nearly a century of prohibition.

(DELTA, British Columbia) — Mat Beren and his friends used to drive by the vast greenhouses of southern British Columbia and joke about how much weed they could grow there.

Years later, it’s no joke. The tomato and pepper plants that once filled some of those greenhouses have been replaced with a new cash crop: marijuana. Beren and other formerly illicit growers are helping cultivate it. The buyers no longer are unlawful dealers or dubious medical dispensaries; it’s the Canadian government.

On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace. Uruguay launched legal sales last year, after several years of planning.

It’s a profound social shift promised by Canadian Prime Minister Justin Trudeau and fueled by a desire to bring the black market into a regulated, taxed system after nearly a century of prohibition.

It also stands in contrast to the United States, where the federal government outlaws marijuana while most states allow medical or recreational use for people 21 and older. Canada’s national approach has allowed for unfettered industry banking, inter-province shipments of cannabis, online ordering, postal delivery and billions of dollars in investment; national prohibition in the U.S. has stifled greater industry expansion there.

Hannah Hetzer, who tracks international marijuana policy for the New York-based Drug Policy Alliance, called Canada’s move “extremely significant,” given that about 25 countries have already legalized the medical use of marijuana or decriminalized possession of small amounts of pot. A few, including Mexico, have expressed an interest in regulating recreational use.

“It’s going to change the global debate on drug policy,” she said. “There’s no other country immediately considering legalizing the nonmedical use of cannabis, but I think Canada will provide almost the permission for other countries to move forward.”

At least 109 legal pot shops are expected to open across the nation of 37 million people next Wednesday, with many more to come, according to an Associated Press survey of the provinces. For now, they’ll offer dried flower, capsules, tinctures and seeds, with sales of marijuana-infused foods and concentrates expected to begin next year.

The provinces are tasked with overseeing marijuana distribution. For some, including British Columbia and Alberta, that means buying cannabis from licensed producers, storing it in warehouses and then shipping it to retail shops and online customers. Others, like Newfoundland, are having growers ship directly to stores or through the mail.

Federal taxes will total $1 per gram or 10 percent, whichever is more. The feds will keep one-fourth of that and return the rest to the provinces, which can add their own markups. Consumers also will pay local sales taxes.

Some provinces have chosen to operate their own stores, like state-run liquor stores in the U.S., while others have OK’d private outlets. Most are letting residents grow up to four plants at home.

Canada’s most populous province, Ontario, won’t have any stores open until next April, after the new conservative government scrapped a plan for state-owned stores in favor of privately run shops. Until then, the only legal option for Ontario residents will be mail delivery — a prospect that didn’t sit well with longtime pot fan Ryan Bose, 48, a Lyft driver.

“Potheads are notoriously very impatient. When they want their weed, they want their weed,” he said after buying a half-ounce at an illicit medical marijuana dispensary in Toronto. “Waiting one or two three days for it by mail, I’m not sure how many will want to do that.”

British Columbia, home of the “B.C. Bud” long cherished by American pot connoisseurs, has had a prevalent marijuana culture since the 1970s, after U.S. draft-dodgers from the Vietnam War settled on Vancouver Island and in the province’s southeastern mountains. But a change in government last year slowed cannabis distribution plans there, too, and it will have just one store ready next Wednesday: a state-run shop in Kamloops, a few hours’ drive northeast of Vancouver. By contrast, Alberta expects to open 17 next week and 250 within a year.

No immediate crackdown is expected for the dozens of illicit-but-tolerated medical marijuana dispensaries operating in British Columbia, though officials eventually plan to close any without a license. Many are expected to apply for private retail licenses, and some have sued, saying they have a right to remain open.

British Columbia’s ministry of public safety is forming a team of 44 inspectors to root out unlawful operations, seize product and issue fines. They’ll have responsibility for a province of 4.7 million people and an area twice as large as California, where the black market still dwarfs the legal market that arrived in January.

Chris Clay, a longtime Canadian medical marijuana activist, runs Warmland Centre dispensary in an old shopping mall in Mill Bay, on Vancouver Island. He is closing the store Monday until he gets a license; he feared continuing to operate post-legalization would jeopardize his chances. Some of his eight staff members will likely have to file for unemployment benefits in the meantime.

“That will be frustrating, but overall I’m thrilled,” Clay said. “I’ve been waiting decades for this.”

The federal government has licensed 120 growers, some of them enormous. Canopy Growth, which recently received an investment of $4 billion from Constellation Brands, whose holdings include Corona beer, Robert Mondavi wines and Black Velvet whiskey, is approved for 5.6 million square feet (520,000 square meters) of production space across Canada. Its two biggest greenhouses are near the U.S. border in British Columbia.

Beren, a 23-year cannabis grower, is a Canopy consultant.

“We used to joke around all the time when we’d go to Vancouver and drive by the big greenhouses on the highway,” he said. “Like, ‘Oh man, someday. It’d be so awesome if we could grow cannabis in one of these greenhouses.’ We drive by now, and we’re like, ‘Oh, we’re here.’”

Next to Canopy’s greenhouse in Delta is another huge facility, Pure Sunfarms, a joint venture between a longtime tomato grower, Village Farms International, and a licensed medical marijuana producer, Emerald Health Therapeutics. Workers pulled out the remaining tomato plants last winter and got to work renovating the greenhouse as a marijuana farm, installing equipment that includes lights and accordion-shaped charcoal vents to control the plant’s odor. By 2020, the venture expects to move more than 165,000 pounds (75,000 kg) of bud per year.

Some longtime illegal growers who operate on a much smaller scale worry they won’t get licensed or will get steamrolled by much larger producers. Provinces can issue “micro-producer” licenses. But in British Columbia, where small-time pot growers helped sustain rural economies as the mining and forestry industries cratered, the application period hasn’t opened yet.

Sarah Campbell of the Craft Cannabis Association of BC said many small operators envision a day when they can host visitors who can tour their operations and sample the product, as wineries do.

Officials say they intend to accommodate craft growers but first need to ensure there is enough cannabis to meet demand when legalization arrives. Hiccups are inevitable, they say, and tweaks will be needed.

“Leaving it to each province to decide what’s best for their communities and their citizens is something that’s good,” said Gene Makowsky, the Saskatchewan minister who oversees the province’s Liquor and Gaming Authority. “We’ll be able to see if each law is successful or where we can do better in certain areas.”

British Columbia safety minister Mike Farnworth said he learned two primary lessons by visiting Oregon and Washington, U.S. states with recreational marijuana. One was not to look at the industry as an immediate cash cow, as it will take time to displace the black market. The other was to start with relatively strict regulations and then loosen them as needed, because it’s much harder to tighten them after the fact.

Legalization will be a process more than a date, Farnworth said.

“Oct. 17th is actually not going to look much different than it does today,” he said.

Source: http://time.com/5421443/canada-legal-marijuana-sales/

Marijuana Company of America $MCOA Applies for Uplisting to OTCQB and Finalizes S1 Registration Statement for Anticipated Equity Financing; Announces New Independent Director and Chief Financial Officer $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:00 AM on Thursday, October 11th, 2018

15233 mcoa

  • Announced that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets
  • Additionally, the Company is in the process of finalizing a registration statement on Form S-1 that the Company intends to file with the Securities and Exchange Commission (SEC), in conjunction with an anticipated equity line of financing that will allow the Company, once the S-1 is effective, to raise up to $10 million.

Escondido, California–(October 11, 2018) – Marijuana Company of America Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets.

Additionally, the Company is in the process of finalizing a registration statement on Form S-1 that the Company intends to file with the Securities and Exchange Commission (SEC), in conjunction with an anticipated equity line of financing that will allow the Company, once the S-1 is effective, to raise up to $10 million. The Company’s application to uplist to the OTCQB tier is a condition for both the equity line of financing and for the Form S-1 registration statement.

Donald Steinberg, MCOA President and CEO commented: “Our goal is to obtain the necessary capital through our S1 to capitalize on the host of opportunities available in the cannabis and hemp industry right now. Also, moving to a higher OTC Markets reporting tier will help to provide better access to institutional investors, broaden our shareholder base, and provide greater credibility with the Company’s partners, clients, stakeholders, and customers, as well as with the wider investment community.”

The OTCQB tier increases transparency, reporting standards, management certification and compliance requirements. Further, the majority of broker dealers trade stocks on the OTCQB and historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

On August 31, 2018, the Company engaged Mr. Jesus Quintero as its new Chief Financial Officer, and on September 19, 2018, appointed Robert Coale as an independent director.

Mr. Quintero has served as a financial consultant to several multi-million dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance, and held senior finance positions with Avnet, Inc., Latin Node, Inc., Globetel Communications Corp. and Telefonica of Spain. His prior experience also includes tenure with Price Waterhouse and Deloitte & Touche. Mr. Quintero earned a B.S. in Accounting from St. John’s University and is a certified public accountant.

Mr. Coale brings years of experience in business consulting, private equity investments, financial and strategic joint venture facilitation, including telecommunications, banking, fund raising, non-profit, retirement, entertainment, licensing, gateway interface/merchant processing, real estate development, and strategic planning. Mr. Coale holds a Master’s in Business Administration, with an emphasis on International Marketing and Strategic Planning from Pepperdine University awarded in 1992; a Bachelor of Science with an emphasis in Finance from the University of Southern California awarded in 1982.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com

hempSMART.com

NetworkNewsWires/MCOA

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Food and Drug Administration #FDA confirms nonclinical and manufacturing requirements #Tetra $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:56 AM on Thursday, October 11th, 2018

Logo tetrabiopharma rgb web

  • Received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™Â mucoadhesive product
  • Meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable
  • The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002

ORLEANS, Ontario, Oct. 11, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™Â mucoadhesive product.   The meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable.

The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002.  The FDA also provided feedback on the chemistry and manufacturing aspects of the drug development plan.  The FDA further confirmed that the product control strategy, ensuring the identity, potency, purity and quality of the PPP002 buccal tablets was acceptable thereby determining that Tetra Bio-Pharma’s plan is on track for drug approval.

“We have now completed our meetings with the U.S. FDA and Tetra is well on its way to finalizing the development plan to bring PPP002 to market,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma. “With both the Type B and C meetings now behind us, we are able to move forward with executing the clinical program for PPP002 and subsequently submit the New Drug Application to commercialize PPP002.”

Tetra, along with its partner IntelGenx Corp, is developing this product in the United States under the accelerated 505(b)(2) pathway for the indication of chemotherapy-induced nausea and vomiting, and anorexia and weight loss in people with AIDS. These are the same indications that have already been approved for Marinol®.  The 505(b)(2) speciality Contract Research Organization, Camargo, is guiding the regulatory submissions to the FDA. Tetra is also developing PPP002 in Canada as an adjunct therapy for opioid reduction in patients with chronic pain.

According to the International Agency for Research on Cancer, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US $1.88 billion by 2020, an increase from its 2013 valuation of US$1.28 billion. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ can gain significant market share within three years of its launch in the USA.

About Tetra Bio-Pharma Inc.

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP002, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Wednesday, October 10th, 2018

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Room for expansion
  • Facility projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all greenhouses
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

Marijuana Company of America $MCOA Appoints Ian Harvey as Global Sales Director of hempSMART(TM) in Preparation of 2019 Launch in Europe $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, October 9th, 2018

15233 mcoa

  • Company has appointed Ian Harvey as the Global Sales Director of its wholly-owned UK subsidiary hempSMART™, Ltd. in preparation for the Company’s January 2019 product launch in Europe.
  • Under the guidance of Ian Harvey, hempSMART is preparing to launch its successful Network Marketing program and industrial hemp derived Cannabidiol (CBD) product line in Europe in January 2019, starting with the United Kingdom.
  • Pre-registration for the UK is available by visiting www.hempsmart.co.uk.

Escondido, California–(October 9, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that the Company has appointed Ian Harvey as the Global Sales Director of its wholly-owned UK subsidiary hempSMART™, Ltd. in preparation for the Company’s January 2019 product launch in Europe.

Under the guidance of Ian Harvey, hempSMART is preparing to launch its successful Network Marketing program and industrial hemp derived Cannabidiol (CBD) product line in Europe in January 2019, starting with the United Kingdom. Pre-registration for the UK is available by visiting www.hempsmart.co.uk.

Ian Harvey has been involved in the direct sales industry for over 35 years. Mr. Harvey has worked for and helped to develop several successful Blue Chip corporations in countries around the world including Japan, South Africa, the United States, and numerous European countries. He has several years of experience launching new product brands, training programs, and implementing strategic approaches designed to capture large networks of loyal customers on an international level.

Donald Steinberg, MCOA CEO, commented, “We are very excited to add Ian Harvey to our hempSMART team. Throughout my career I have successfully launched several companies internationally, and with Mr. Harvey’s experience and hempSMART’s incredible product formulations, I see a unique opportunity to establish and grow our brand to become a household name in Europe and eventually worldwide.”

Ian Harvey commented, “I am extremely excited to be appointed as the Global Sales Director for hempSMART. My goal is to make hempSMART a brand name recognized in households worldwide. It is a great feeling to know many lives will be transformed as we rollout out our expansion plans. Our new Regional support center based in the UK is gearing up to get ready for what is expected to be a massive success story in Europe. We have started our prelaunch in the UK with a vision of being fully launched in January. Once launched, we will then move forward with a very ambitious rollout program to include several European countries along with other Global markets.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Harvest Underway At #Marijuana Company Of America’s $MCOA #CBD Hemp Operation In Scio, Oregon $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:40 AM on Tuesday, October 2nd, 2018

15233 mcoa

  • Harvest has begun at the farm
  • Over the next 10 days the team in Scio will harvest this year’s crop, which consists of approximately 36,000 high yielding CBD hemp plants that were grown in an orchard style cultivation on 33 acres

ESCONDIDO, Calif., Oct. 02, 2018  – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (CSE: GHG/ OTC: GBHPF/ FRANKFURT: GHG) (the “Partners”) are pleased to provide an update on their high yielding CBD hemp project in Scio, Oregon.

Harvest
Harvest has begun at the farm. Over the next 10 days the team in Scio will harvest this year’s crop, which consists of approximately 36,000 high yielding CBD hemp plants that were grown in an orchard style cultivation on 33 acres. The team planted six different cultivars this year to determine which would be the optimal hemp variety to grow in the coming year. The team continues to evaluate hemp cultivars that will provide higher CBD yields and a reduced flowering period, which will allow the team to complete the harvest earlier in the year prior to the fall rains.

Preparation for Extraction
Once the hemp is harvested, it will be dried in preparation for storage prior to processing. Drying this season will take place in the project’s four recently completed greenhouses on the farm and will utilize a traditional hanging method, as well as testing an innovative rack drying system. Prior to next season’s harvest, the Partners will construct a permanent drying facility on site. Once the hemp is dried to a 10-12% moisture content, it can be stored with little or no cannabinoid/plant matter degradation, prior to extraction.

Greenhouses
The team has now completed the setup of the first four of five greenhouses, giving the project 15,000+ sq. ft. of active greenhouse space for its drying and cloning operations. A fifth greenhouse (already purchased) will be installed after the drying of this year’s crop is complete. This will increase the active greenhouse space at the project to over 19,000 sq. ft. An additional 20,000 sq. ft. of greenhouse space will be purchased in October as part of further project expansion, with the vision of implementing a year round perpetual harvest model to enhance revenue generation and cash flow, and increasing the size of the cloning operation to be able to supply clones to the local farming community.

The team has now started its cloning operations for the winter crop, which will utilize the current and future greenhouses. Management is exploring opportunities to maximize production by developing beneficial relationships that will help optimize the Project’s profit potential through R&D, data collection and analysis.

Discussions with local Farmers
With the success of this year’s hemp cultivation on display at the farm, it has attracted the attention of the local community and many local farmers that are interested in growing hemp as hemp generates a far greater Return On Investment per acre than any other crop they are currently growing. The Project’s stated goal has been to use 2018 as an initial commercial trial and then to significantly expand the acreage under cultivation in the coming years. Management is currently in discussions with a number of these local farmers regarding contract farming and share cropping for the project, starting next year.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG), is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The Company is headquartered in Vancouver, British Columbia, with hemp cultivation operations in New Brunswick and Oregon. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/91c6e0d5-8f9a-4b46-a157-e7d6f6567932
http://www.globenewswire.com/NewsRoom/AttachmentNg/2e31feb6-b422-485b-bef9-7972db707e8c

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Friday, September 28th, 2018

681747 5720 copy 2

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Facility projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all greenhouses
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

#Cannabis-laced drinks could be a US$600m market in US by 2022 $NBUD.ca $TAP $WEED.ca $KO

Posted by AGORACOM-JC at 10:18 AM on Friday, September 28th, 2018
  • Beverages with CBD (cannabidiol) or THC (tetrahydrocannabinol) ingredients could grow to capture about 20 per cent of the US market for edible pot products by 2022, up from 6 per cent of edibles sold now
  • Canaccord sees the demand for beverages featuring CBD, the non-psychoactive compound in marijuana, reaching US$260 million by 2022, up from the “negligible revenue” the limited number of drinks contributes now, while THC-based drinks could reach US$340 million, up from US$106 million expected this year

Sep 27, 2018 (Euclid Infotech Ltd via COMTEX) — Drinks infused with marijuana-derived compounds could swell to become a US$600 million market in the US within the next four years, outpacing the growth of other categories of retail cannabis products, according to analysts at Canaccord Genuity.

Beverages with CBD (cannabidiol) or THC (tetrahydrocannabinol) ingredients could grow to capture about 20 per cent of the US market for edible pot products by 2022, up from 6 per cent of edibles sold now, Canaccord’s Bobby Burleson wrote in a note. It’s an opportunity mainstream beer and soda makers are eager to take part in – Corona-parent Constellation Brands Inc became the largest stakeholder in Canadian pot cultivator Canopy Growth Corp earlier this year, while Molson Coors Canada formed a joint venture with Hexo Corp. Also, Coca-Cola Co said it’s exploring the idea.

“Interest has spiked from the beer industry on mounting evidence of a substitution relationship between cannabis and alcohol, while large soda companies increasingly view CBD as a natural fit within their strategically important wellness offerings,” Mr Burleson wrote.

Canaccord sees the demand for beverages featuring CBD, the non-psychoactive compound in marijuana, reaching US$260 million by 2022, up from the “negligible revenue” the limited number of drinks contributes now, while THC-based drinks could reach US$340 million, up from US$106 million expected this year.

Source: https://www.marketwatch.com/press-release/united-states-cannabis-laced-drinks-could-be-a-us600m-market-in-us-by-2022-2018-09-27

INTERVIEW: North Bud Farms $NBUD.ca Discusses Licensing of #Cannabinoid Infusion Technology for Food and Beverage Platform

Posted by AGORACOM-JC at 4:02 PM on Thursday, September 27th, 2018